VAI-SU2C Epigenetics Dream Team

7 results.

March 27, 2024 Combining epigenetic cancer medications may have benefit for colorectal cancers and other tumor types

GRAND RAPIDS, Mich. (March 27, 2024) — A pair of medications that make malignant cells act as if they have a virus could hold new promise for…

August 3, 2023 Making an impact in the real-world: Five things to know about the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team

Since October 2014, the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team has supported and launched breakthrough clinical trials that explore potential new…

April 4, 2019 Blocking epigenetic “Swiss army knife” may be a new strategy for treating colorectal cancer

GRAND RAPIDS, Mich. (April 4, 2019) — A new study out today in Cancer Cell shows that blocking specific regions of a protein called…

October 12, 2017 Stand Up To Cancer awards $5.5 million to VARI for cancer clinical trials to enhance immunotherapy

GRAND RAPIDS, Mich. (Oct. 12, 2017)—Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team (VARI-SU2C) scientists have been awarded two…

March 7, 2017 New drug combination targets aggressive blood cancer

Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial

GRAND RAPIDS, Mich. (March 7,…

August 29, 2016 Vitamin C may boost effectiveness of acute myeloid leukemia treatment

EDITOR’S NOTE: Maintaining proper nutrition is an important part of cancer therapy. Patients are urged to consult their doctors before making any change to their…

October 20, 2014 Stand Up To Cancer Epigenetics Dream Team continues with $7.5 million funding from Van Andel Research Institute

Grand Rapids, Michigan (October 20, 2014)— The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus…